BIOMAT Database Logo BIOMAT Database Logo

A novel multidrug therapy for difficult cyclosporine-resistant focal segmental glomerulosclerosis. 2009

Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005923 Glomerulosclerosis, Focal Segmental A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE. Glomerulonephritis, Focal Sclerosing,Hyalinosis, Segmental Glomerular,Focal Segmental Glomerulosclerosis,Glomerulosclerosis, Focal,Hyalinosis, Segmental,Segmental Glomerular Hyalinosis,Focal Glomerulosclerosis,Focal Sclerosing Glomerulonephritides,Focal Sclerosing Glomerulonephritis,Glomerular Hyalinosis, Segmental,Glomerulonephritides, Focal Sclerosing,Sclerosing Glomerulonephritides, Focal,Sclerosing Glomerulonephritis, Focal,Segmental Glomerulosclerosis, Focal,Segmental Hyalinosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis.
April 1995, Journal of the American Society of Nephrology : JASN,
Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
Therapy of focal segmental glomerulosclerosis with cyclosporine A.
April 1987, Pediatric nephrology (Berlin, Germany),
Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis.
March 2016, Pediatrics international : official journal of the Japan Pediatric Society,
Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
Therapy-resistant focal and segmental glomerulosclerosis.
July 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
Tacrolimus for the treatment of focal segmental glomerulosclerosis resistant to cyclosporine A.
December 2006, Pediatric nephrology (Berlin, Germany),
Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis.
August 2017, Current medical research and opinion,
Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
Cyclosporine therapy in steroid-dependent or steroid-resistant idiopathic focal and segmental glomerulosclerosis.
January 2016, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
Idiopathic focal segmental glomerulosclerosis resistant to ciclosporin-A therapy.
January 1988, Nephron,
Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone.
June 1998, Pediatric nephrology (Berlin, Germany),
Eishin Oki, and Kazushi Tsuruga, and Masanobu Kudo, and Koji Tsugawa, and Koichi Suzuki, and Hiroshi Tanaka
"Presumed" Primary Focal Segmental Glomerulosclerosis: A Novel Nuance for Steroid Therapy.
January 2022, Kidney international reports,
Copied contents to your clipboard!